PE20181322A1 - Anticuerpo anti-pd1 y sus metodos de uso - Google Patents
Anticuerpo anti-pd1 y sus metodos de usoInfo
- Publication number
- PE20181322A1 PE20181322A1 PE2018000059A PE2018000059A PE20181322A1 PE 20181322 A1 PE20181322 A1 PE 20181322A1 PE 2018000059 A PE2018000059 A PE 2018000059A PE 2018000059 A PE2018000059 A PE 2018000059A PE 20181322 A1 PE20181322 A1 PE 20181322A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- cancer
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212851P | 2015-09-01 | 2015-09-01 | |
| US201562216043P | 2015-09-09 | 2015-09-09 | |
| US201562257195P | 2015-11-18 | 2015-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181322A1 true PE20181322A1 (es) | 2018-08-14 |
Family
ID=56896841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000059A PE20181322A1 (es) | 2015-09-01 | 2016-09-01 | Anticuerpo anti-pd1 y sus metodos de uso |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10323091B2 (enExample) |
| EP (1) | EP3344656A1 (enExample) |
| JP (3) | JP6869987B2 (enExample) |
| KR (2) | KR20220131277A (enExample) |
| CN (2) | CN114605548A (enExample) |
| AU (2) | AU2016317915B2 (enExample) |
| CA (1) | CA2993432A1 (enExample) |
| CL (2) | CL2018000490A1 (enExample) |
| CO (1) | CO2017013405A2 (enExample) |
| EA (1) | EA201890630A1 (enExample) |
| HK (1) | HK1257840A1 (enExample) |
| IL (2) | IL257281B (enExample) |
| MA (1) | MA48579A (enExample) |
| MX (1) | MX2018002315A (enExample) |
| PE (1) | PE20181322A1 (enExample) |
| SG (1) | SG10201913276WA (enExample) |
| WO (1) | WO2017040790A1 (enExample) |
Families Citing this family (195)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CA2925421C (en) | 2013-09-24 | 2023-08-29 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
| EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| MA48579A (fr) * | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
| WO2017058859A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
| DK3370768T3 (da) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | Antistoffer som specifikt binder pd-1 og anvendelser deraf |
| CA3004748C (en) | 2015-11-18 | 2021-11-16 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| TWI765875B (zh) | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
| TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS |
| JP7258747B2 (ja) | 2016-10-28 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法 |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| AU2017373945B2 (en) | 2016-12-07 | 2025-01-23 | Agenus Inc. | Antibodies and methods of use thereof |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| SG11201907846VA (en) | 2017-02-28 | 2019-09-27 | Sanofi Sa | Therapeutic rna |
| WO2018175279A2 (en) * | 2017-03-20 | 2018-09-27 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
| SG10202110594UA (en) | 2017-03-31 | 2021-11-29 | Bristol Myers Squibb Co | Methods of treating tumor |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| WO2018191502A2 (en) | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
| WO2018204363A1 (en) | 2017-05-01 | 2018-11-08 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| AU2018277559A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent |
| CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| WO2018220446A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| JP7780857B2 (ja) | 2017-06-01 | 2025-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| MY199715A (en) | 2017-06-05 | 2023-11-20 | Janssen Biotech Inc | Antibodies that specifically bind pd-1 and methods of use |
| WO2018234862A1 (en) | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
| CN110914258A (zh) | 2017-07-14 | 2020-03-24 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
| ES2975221T3 (es) | 2017-08-03 | 2024-07-04 | Amgen Inc | Muteínas de interleucina-21 y métodos de tratamiento |
| CN107383174B (zh) * | 2017-08-21 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种能与pd-1特异性结合的肿瘤抑制肽及其用途 |
| CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
| KR102760684B1 (ko) | 2017-09-29 | 2025-01-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 조성물 및 방법 |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| AU2018360790A1 (en) | 2017-11-06 | 2020-06-11 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| KR20200088386A (ko) | 2017-11-14 | 2020-07-22 | 화이자 인코포레이티드 | Ezh2 억제제 병용 요법 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| JOP20200172A1 (ar) | 2018-01-12 | 2020-07-12 | Amgen Inc | الأجسام المضادة لـ pd-1 وطرق العلاج |
| CN111868091A (zh) | 2018-01-16 | 2020-10-30 | 百时美施贵宝公司 | 用抗tim3抗体治疗癌症的方法 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| EP3743061A1 (en) | 2018-01-22 | 2020-12-02 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| MX2020007526A (es) | 2018-01-22 | 2020-09-09 | Bristol Myers Squibb Co | Composiciones y metodos para tratar el cancer. |
| CA3090552A1 (en) | 2018-02-07 | 2019-08-15 | Imugene Limited | A vaccine composition and uses thereof |
| KR102608723B1 (ko) | 2018-02-23 | 2023-12-01 | 유큐(베이징) 바이오파마 코., 엘티디 | 항―ｐｄ－１ 항체 및 그의 용도 |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| EP3774903A1 (en) | 2018-04-04 | 2021-02-17 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
| WO2019195621A1 (en) * | 2018-04-04 | 2019-10-10 | Immutics, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| MX2020011234A (es) | 2018-04-25 | 2020-11-11 | Innate Tumor Immunity Inc | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). |
| IL278400B2 (en) | 2018-05-07 | 2024-03-01 | Genmab As | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| JP2021527714A (ja) | 2018-06-20 | 2021-10-14 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 抗ｐｄ−１抗体及びその使用 |
| US20210238287A1 (en) | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
| ES2930171T3 (es) | 2018-08-16 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores de NLRP3 derivados de imidazo[4,5-C]quinolina |
| EP3837015B1 (en) | 2018-08-16 | 2024-02-14 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
| WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| JP2022512642A (ja) | 2018-10-09 | 2022-02-07 | ブリストル－マイヤーズ スクイブ カンパニー | がんを治療するための抗ＭｅｒＴＫ抗体 |
| JP7453219B2 (ja) * | 2018-10-11 | 2024-03-19 | インヒブリックス， インコーポレイテッド | Ｐｄ－１単一ドメイン抗体およびその治療用組成物 |
| LT3866850T (lt) | 2018-10-19 | 2024-09-10 | Bristol-Myers Squibb Company | Kompleksinė melanomos terapija |
| EP3870609A1 (en) | 2018-10-23 | 2021-09-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| CN118667024A (zh) * | 2018-11-01 | 2024-09-20 | 生物发明国际公司 | 新型拮抗性抗tnfr2抗体分子 |
| WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| HUE067601T2 (hu) * | 2018-11-14 | 2024-10-28 | Regeneron Pharma | PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére |
| NZ777032A (en) | 2018-11-16 | 2024-07-26 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| AU2019382505A1 (en) | 2018-11-19 | 2021-05-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-PD-1 antibodies and uses thereof |
| EP3891508A1 (en) | 2018-12-04 | 2021-10-13 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
| EP3666905A1 (en) | 2018-12-11 | 2020-06-17 | Sanofi | E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer |
| JP2022514702A (ja) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗ｐｄ－１／ｉｌ－７分子 |
| AU2019409805A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/SIRPA molecule |
| JP7340021B2 (ja) | 2018-12-23 | 2023-09-06 | エフ． ホフマン－ラ ロシュ アーゲー | 予測腫瘍遺伝子変異量に基づいた腫瘍分類 |
| KR102865929B1 (ko) | 2019-01-14 | 2025-09-29 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| JP7373571B2 (ja) | 2019-01-14 | 2023-11-02 | イネイト・テューマー・イミュニティ・インコーポレイテッド | がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン |
| EP3911417B1 (en) | 2019-01-14 | 2022-10-26 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators , for use in the treatment of cancer |
| KR20210114983A (ko) | 2019-01-14 | 2021-09-24 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| AU2020210614A1 (en) | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| JP2022527177A (ja) | 2019-03-28 | 2022-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| JP2022526960A (ja) | 2019-03-28 | 2022-05-27 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| BR112021022135A2 (pt) | 2019-05-06 | 2023-02-28 | Univ Brown | Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| JP7354306B2 (ja) * | 2019-06-27 | 2023-10-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子 |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| MX2022003487A (es) | 2019-09-25 | 2022-04-25 | Bristol Myers Squibb Co | Biomarcador compuesto para terapia de cancer. |
| JP2022553821A (ja) | 2019-11-05 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍ－タンパク質アッセイおよびその使用 |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
| WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| KR20220118481A (ko) | 2019-12-19 | 2022-08-25 | 브리스톨-마이어스 스큅 컴퍼니 | Dgk 억제제 및 체크포인트 길항제의 조합물 |
| WO2021142203A1 (en) | 2020-01-10 | 2021-07-15 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2021142276A1 (en) * | 2020-01-12 | 2021-07-15 | Vanderbilt University | Human antibodies to rift valley fever virus |
| US20230090446A1 (en) | 2020-01-28 | 2023-03-23 | Universite De Strasbourg | Antisense oligonucleotide targeting linc00518 for treating melanoma |
| JP2023512276A (ja) | 2020-01-30 | 2023-03-24 | オーエヌエー セラピューティクス エセ．エレ． | 癌及び癌転移の治療のための併用療法 |
| KR20220139915A (ko) | 2020-02-06 | 2022-10-17 | 브리스톨-마이어스 스큅 컴퍼니 | Il-10 및 그의 용도 |
| AU2021232158A1 (en) | 2020-03-06 | 2022-09-29 | Ona Therapeutics, S.L. | Anti-CD36 antibodies and their use to treat cancer |
| EP4114398A1 (en) | 2020-03-06 | 2023-01-11 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
| CN115768792A (zh) | 2020-03-23 | 2023-03-07 | 百时美施贵宝公司 | 抗ccr8抗体用于治疗癌症 |
| EP4147053A1 (en) | 2020-05-07 | 2023-03-15 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
| US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| CA3193688A1 (en) | 2020-10-09 | 2022-04-14 | Vladimir Lazar | Novel prediction method and gene signatures for the treatment of cancer |
| JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル－マイヤーズ スクイブ カンパニー | 肺がんのためのｌａｇ－３アンタゴニスト療法 |
| MX2023004847A (es) | 2020-10-28 | 2023-07-11 | Ikena Oncology Inc | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. |
| WO2022108931A2 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| MX2023007301A (es) | 2020-12-17 | 2023-07-04 | Ose Immunotherapeutics | Moleculas bifuncionales anti-pd1/il-7. |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| PL4267105T3 (pl) | 2020-12-28 | 2025-06-30 | Bristol-Myers Squibb Company | Kompozycje przeciwciał i metody ich stosowania |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| WO2022165275A2 (en) | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
| EP4284516A1 (en) | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| IL307262A (en) | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| JP2024515263A (ja) | 2021-04-09 | 2024-04-08 | オーエスイー・イミュノセラピューティクス | 改善された特性を有する二機能性分子のための新規足場構造 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| CA3226281A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| JP2024536383A (ja) | 2021-10-06 | 2024-10-04 | ジェンマブ エー／エス | 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| MX2024008831A (es) | 2022-01-26 | 2024-07-25 | Bristol Myers Squibb Co | Terapia combinada para carcinoma hepatocelular. |
| EP4482866A1 (en) | 2022-02-25 | 2025-01-01 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| EP4490191A1 (en) | 2022-03-08 | 2025-01-15 | Alentis Therapeutics AG | Use of anti-claudin-1 antibodies to increase t cell availability |
| CN118871451A (zh) | 2022-03-18 | 2024-10-29 | 百时美施贵宝公司 | 分离多肽的方法 |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| CN119731651A (zh) | 2022-04-08 | 2025-03-28 | 百时美施贵宝公司 | 三级淋巴结构的机器学习标识、分类和量化 |
| TW202413412A (zh) | 2022-05-12 | 2024-04-01 | 丹麥商珍美寶股份有限公司 | 在組合療法中能夠結合到ｃｄ２７之結合劑 |
| CN119562830A (zh) | 2022-06-02 | 2025-03-04 | 百时美施贵宝公司 | 抗体组合物及其使用方法 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
| EP4561599A1 (en) | 2022-07-27 | 2025-06-04 | Astrazeneca AB | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
| WO2024023246A1 (en) * | 2022-07-28 | 2024-02-01 | Philogen S.P.A. | Antibody binding to pd1 |
| JP2025533015A (ja) | 2022-09-30 | 2025-10-03 | アレンティス セラピューティクス アクチェンゲゼルシャフト | 薬物抵抗性肝細胞癌の処置 |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| KR20250113508A (ko) | 2022-12-01 | 2025-07-25 | 메디뮨 리미티드 | 항-pd-l1 및 항-cd73 항체를 포함하는 암 치료를 위한 병용 요법 |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| AU2023409221A1 (en) | 2022-12-21 | 2025-06-12 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024150177A1 (en) | 2023-01-11 | 2024-07-18 | Advesya | Treatment methods for solid tumors |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2024175699A1 (en) | 2023-02-23 | 2024-08-29 | Imcheck Therapeutics | Combination of btn3a activating antibody and immune checkpoint inhibitors |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2024236048A1 (en) | 2023-05-16 | 2024-11-21 | Nh Theraguix | Combination therapy for treating tumors with radiotherapy |
| WO2024261239A1 (en) | 2023-06-23 | 2024-12-26 | Imcheck Therapeutics | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
Family Cites Families (290)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| IL108501A (en) | 1994-01-31 | 1998-10-30 | Mor Research Applic Ltd | Antibodies and pharmaceutical compositions containing them |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6027947A (en) | 1996-08-20 | 2000-02-22 | Ramtron International Corporation | Partially or completely encapsulated top electrode of a ferroelectric capacitor |
| US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| NZ334914A (en) | 1996-10-01 | 2000-09-29 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| EP1009429B1 (en) | 1997-08-29 | 2009-07-08 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| WO1999021537A1 (fr) | 1997-10-28 | 1999-05-06 | Bando Chemical Industries, Ltd. | Feuille de timbre cutane et procede de production d'une feuille de base pour timbre |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| JP4620251B2 (ja) | 1998-08-10 | 2011-01-26 | アンチジェニックス・インコーポレイテッド | Ｃｐｇおよびサポニンアジュバントの組成物並びにその方法 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| DK1212422T3 (da) | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DK1233987T3 (da) | 1999-11-29 | 2009-09-28 | Bac Ip B V | Immobiliserede enkelt-domæne antigenbindende molekyler |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| EP1125905A1 (en) | 2000-02-16 | 2001-08-22 | Pepscan Systems B.V. | Segment synthesis |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| ATE494304T1 (de) * | 2000-06-16 | 2011-01-15 | Human Genome Sciences Inc | Immunspezifisch bindende antikörper gegen blys |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| EP1377830A2 (en) | 2001-02-16 | 2004-01-07 | Pepscan Systems B.V. | Arrays for determining binding of biomolecules |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| EP1445264B1 (en) | 2001-07-31 | 2011-09-14 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP1660534A2 (en) | 2003-08-22 | 2006-05-31 | MedImmune, Inc. | Humanization of antibodies |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| WO2006042237A2 (en) | 2004-10-06 | 2006-04-20 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
| CN105085678B (zh) * | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| US20060240006A1 (en) | 2005-04-20 | 2006-10-26 | Chishih Chu | Novel antibody structures derived from human germline sequences |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| PL2397156T3 (pl) | 2005-06-08 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1) |
| TW200813091A (en) * | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| WO2008083174A2 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| CN104945508B (zh) * | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| US9243052B2 (en) | 2007-08-17 | 2016-01-26 | Daniel Olive | Method for treating and diagnosing hematologic malignancies |
| HUE037265T2 (hu) * | 2007-08-21 | 2018-08-28 | Amgen Inc | Humán c-fms antigént kötõ proteinek |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| AU2008303796B2 (en) * | 2007-09-26 | 2014-09-18 | Amgen Inc. | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| PL3208612T3 (pl) | 2008-04-09 | 2020-03-31 | Genentech, Inc. | Kompozycje i sposoby leczenia chorób o podłożu immunologicznym |
| KR20110044992A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| KR101847107B1 (ko) | 2008-07-08 | 2018-04-10 | 인사이트 홀딩스 코포레이션 | 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| WO2010102278A1 (en) | 2009-03-06 | 2010-09-10 | President And Fellows Of Harvard College | Methods and compositions for the generation and maintenance of regulatory t cells |
| EP2432488A4 (en) * | 2009-03-20 | 2014-01-08 | Amgen Inc | SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS |
| KR102010827B1 (ko) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| HUE031371T2 (en) | 2010-08-23 | 2017-07-28 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012129520A1 (en) | 2011-03-24 | 2012-09-27 | Texas Tech University System | Tcr mimic antibodies as vascular targeting tools |
| EP2691112B1 (en) | 2011-03-31 | 2018-05-23 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| PE20141271A1 (es) | 2011-04-01 | 2014-10-08 | Sloan Kettering Inst Cancer | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2723381A4 (en) | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS |
| ES2893855T3 (es) | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| JP6368308B2 (ja) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのｖｉｓｔａ調節剤 |
| EP3679950A1 (en) | 2012-10-12 | 2020-07-15 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
| US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| WO2014093936A1 (en) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| ES2721168T3 (es) | 2013-01-11 | 2019-07-29 | Dingfu Biotarget Co Ltd | Agentes para tratar tumores, uso y método de los mismos |
| EP3292873B1 (en) | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| AU2014220957A1 (en) | 2013-02-22 | 2015-07-30 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| WO2014144080A2 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
| US10047137B2 (en) | 2013-04-05 | 2018-08-14 | Versitech Limited | Antibodies against novel PD1 isoforms and uses thereof |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| CA3175360C (en) * | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| GB201311487D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| MX384142B (es) | 2013-07-16 | 2025-03-14 | Genentech Inc | Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer. |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| PL3036258T3 (pl) | 2013-08-22 | 2023-12-11 | The Council Of The Queensland Institute Of Medical Research | Modulowanie receptora dla leczenia raka i infekcji wirusowych |
| US10077305B2 (en) | 2013-09-10 | 2018-09-18 | Medimmune Limited | Antibodies against PD-1 and uses thereof |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| EA034666B1 (ru) * | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JP2016540042A (ja) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ， インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
| US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
| JP6879739B2 (ja) | 2013-11-25 | 2021-06-02 | フェイムウェイヴ リミテッド | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| MX2016007965A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| JP6622703B2 (ja) | 2013-12-20 | 2019-12-18 | インターベット インターナショナル ベー． フェー． | アンタゴニストの、抗イヌｐｄ−１抗体 |
| US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015134605A1 (en) | 2014-03-05 | 2015-09-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| EP3134546A4 (en) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| CA2949121A1 (en) | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| US20160031990A1 (en) | 2014-05-29 | 2016-02-04 | Medlmmune, Llc | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| EP3166975A1 (en) | 2014-07-07 | 2017-05-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| CA2955788C (en) | 2014-07-22 | 2024-01-16 | Ziyong Sun | Anti-pd-1 antibodies |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| EP3936145A1 (en) | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| SMT202200285T1 (it) | 2014-08-11 | 2022-09-14 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1 |
| TN2017000024A1 (en) | 2014-08-19 | 2018-07-04 | Merck Sharp & Dohme | Anti-tigit antibodies. |
| EP3183269A2 (en) | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| EP3218409A2 (en) | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| KR20170080697A (ko) | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US20180133313A1 (en) | 2014-12-16 | 2018-05-17 | Bristol-Myers Squibb Company | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| MX389267B (es) | 2014-12-23 | 2025-03-20 | Bristol Myers Squibb Co | Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit). |
| EP3253413A2 (en) | 2015-02-06 | 2017-12-13 | Kadmon Corporation, LLC | Immunomodulatory agents |
| IL278423B2 (en) | 2015-02-26 | 2024-04-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| WO2016149387A1 (en) | 2015-03-18 | 2016-09-22 | The Johns Hopkins University | Androgen deprivation with immune checkpoint blockade delays the development of castration resistant prostate cancer |
| WO2016168143A1 (en) | 2015-04-14 | 2016-10-20 | Bristol-Myers Squibb Company | IMMUNOASSAY FOR SOLUBLE PROGRAMMED DEATH-1 (sPD-1) PROTEIN |
| WO2016172624A1 (en) | 2015-04-22 | 2016-10-27 | Agenus Inc. | Methods for treating cancer |
| JP2018515474A (ja) | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| CN115109158A (zh) | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
| US20180256715A1 (en) | 2015-05-13 | 2018-09-13 | The Board Of Regents Of The University Of Texas System | Anti-ctla-4 blockade |
| US20160347836A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of hodgkin's lymphoma using an anti-pd-1 antibody |
| WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| HRP20201031T1 (hr) | 2015-05-29 | 2020-10-16 | Agenus Inc. | Anti-ctla-4 protutijela i postupci njihove upotrebe |
| CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| CN108337890B (zh) | 2015-06-23 | 2021-10-15 | 纪念斯隆-凯特琳癌症中心 | 新型pd-1免疫调节剂 |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| RS61532B1 (sr) | 2015-07-14 | 2021-04-29 | Bristol Myers Squibb Co | Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| KR102761886B1 (ko) | 2015-07-30 | 2025-02-06 | 마크로제닉스, 인크. | Pd-1-결합 분자 및 그것의 사용 방법 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MA48579A (fr) * | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
| HUE069796T2 (hu) | 2015-09-25 | 2025-04-28 | Hoffmann La Roche | Anti-TIGIT ellenanyagok és alkalmazásukra szolgáló eljárások |
| KR20180054791A (ko) | 2015-09-28 | 2018-05-24 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | 안정한 항-pd-1 항체 약학적 제조물 및 의료에서의 그의 적용 |
| US10981991B2 (en) | 2015-09-29 | 2021-04-20 | Shanghai Zhangjiang Biotechnology Co., Ltd. | PD-1 antibodies and uses thereof |
| WO2017058859A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
| CA3000404A1 (en) | 2015-10-01 | 2017-04-06 | Potenza Therapeutics, Inc. | Anti-tigit antigen-binding proteins and methods of use thereof |
| MX2018003936A (es) | 2015-10-02 | 2018-07-06 | Symphogen As | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. |
| ES2895034T3 (es) | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
| WO2017079080A1 (en) | 2015-11-02 | 2017-05-11 | The Johns Hopkins University | Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway |
| WO2017079303A1 (en) | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| US10858432B2 (en) | 2015-12-02 | 2020-12-08 | Stcube, Inc. | Antibodies specific to glycosylated PD-1 and methods of use thereof |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| GB201522311D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN105669864B (zh) | 2015-12-23 | 2018-10-16 | 杭州尚健生物技术有限公司 | 抗人程序性死亡受体1抗体及其制备方法和用途 |
| CN109069628A (zh) | 2016-01-14 | 2018-12-21 | Bps生物科学有限公司 | 抗pd-1抗体及其用途 |
| FI3964529T3 (fi) | 2016-01-22 | 2025-06-13 | MabQuest SA | Ei-estäviä PD1-spesifisiä vasta-aineita |
| CN108602892A (zh) | 2016-01-27 | 2018-09-28 | 百时美施贵宝公司 | 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌 |
| WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
| BR112018015291A2 (pt) | 2016-01-28 | 2018-12-18 | Univ Indiana Res & Tech Corp | uso de inibidores de histona desacetilase para melhorar imunoterapias |
| ES2924775T3 (es) | 2016-01-28 | 2022-10-10 | Inst Nat Sante Rech Med | Métodos y composición farmacéutica para el tratamiento del cáncer |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017147368A1 (en) | 2016-02-24 | 2017-08-31 | Oncomed Pharmaceuticals, Inc. | Redirecting immune responses |
| MX2018010361A (es) | 2016-02-29 | 2019-07-08 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| JP2019509282A (ja) | 2016-02-29 | 2019-04-04 | ファウンデーション・メディシン・インコーポレイテッド | 癌の治療方法 |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| AU2017373945B2 (en) * | 2016-12-07 | 2025-01-23 | Agenus Inc. | Antibodies and methods of use thereof |
-
2016
- 2016-09-01 MA MA048579A patent/MA48579A/fr unknown
- 2016-09-01 US US15/254,315 patent/US10323091B2/en active Active
- 2016-09-01 WO PCT/US2016/049913 patent/WO2017040790A1/en not_active Ceased
- 2016-09-01 SG SG10201913276WA patent/SG10201913276WA/en unknown
- 2016-09-01 KR KR1020227028239A patent/KR20220131277A/ko active Pending
- 2016-09-01 HK HK19100195.2A patent/HK1257840A1/zh unknown
- 2016-09-01 PE PE2018000059A patent/PE20181322A1/es unknown
- 2016-09-01 CN CN202210395952.2A patent/CN114605548A/zh active Pending
- 2016-09-01 EP EP16763697.6A patent/EP3344656A1/en active Pending
- 2016-09-01 KR KR1020187007642A patent/KR102434314B1/ko active Active
- 2016-09-01 CN CN201680049891.7A patent/CN107949573B/zh active Active
- 2016-09-01 EA EA201890630A patent/EA201890630A1/ru unknown
- 2016-09-01 JP JP2018530674A patent/JP6869987B2/ja active Active
- 2016-09-01 CA CA2993432A patent/CA2993432A1/en active Pending
- 2016-09-01 MX MX2018002315A patent/MX2018002315A/es unknown
- 2016-09-01 AU AU2016317915A patent/AU2016317915B2/en active Active
-
2017
- 2017-12-26 CO CONC2017/0013405A patent/CO2017013405A2/es unknown
-
2018
- 2018-01-31 IL IL257281A patent/IL257281B/en active IP Right Grant
- 2018-02-22 CL CL2018000490A patent/CL2018000490A1/es unknown
-
2019
- 2019-04-30 US US16/399,262 patent/US10450373B2/en active Active
-
2020
- 2020-04-24 US US16/858,193 patent/US11345755B2/en active Active
- 2020-08-31 CL CL2020002231A patent/CL2020002231A1/es unknown
-
2021
- 2021-01-18 AU AU2021200281A patent/AU2021200281B2/en active Active
- 2021-03-29 JP JP2021055208A patent/JP7230090B2/ja active Active
- 2021-05-05 IL IL282962A patent/IL282962A/en unknown
-
2022
- 2022-05-09 US US17/662,518 patent/US20220372149A1/en not_active Abandoned
-
2023
- 2023-02-09 JP JP2023018480A patent/JP2023053114A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181322A1 (es) | Anticuerpo anti-pd1 y sus metodos de uso | |
| PE20210628A1 (es) | Anticuerpos anti-cd73 y metodos de uso de los mismos | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| PE20190921A1 (es) | Anticuerpos y metodos de su utilizacion | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| MX2019008758A (es) | Anticuerpos anti-cd37 y usos de los mismos. | |
| AR078778A1 (es) | Proteinas de union a antigenos de il-23 | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
| MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| MX2022002315A (es) | Anticuerpos anti-cd96 y sus metodos de uso. | |
| PE20161221A1 (es) | Anticuerpos de il-21 | |
| BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização |